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This bulletin presents key findings regarding the use of sedatives or tranquillisers and anti-depressant in Ireland 
and Northern Ireland from the third drug prevalence survey of households in Ireland and Northern Ireland. A 
representative sample of adults aged between 15 and 64 years was sampled during late 2010 and early 2011.  
The bulletin presents results regarding use of sedatives or tranquillisers and anti-depressants on lifetime (ever used), 
last year (recent use) and last month (current use) prevalence rates. The bulletin also examines age of first use, 
frequency of use, methods of taking the substances, how they were obtained and the profile of those who take 
these substances. The survey was carried out according to standards set by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA).
Key Findings
Ireland Key Findings
n The results from the 2010/11 survey 
show that the prevalence for sedatives 
or tranquillisers for adults aged 15–64 
in Ireland are 14% (lifetime), 7% (last 
year) and 3% (last month). There were 
statistically significant increases in both 
lifetime and last year prevalence since 
2007.
n For anti-depressants, prevalence rates 
among adults aged 15–64 years are 
10% (lifetime), 5% (last year) and 
4% (last month). Statistically significant 
increases were found for last month 
prevalence only.
n In 2011 women were more likely to 
report taking sedatives or tranquillisers 
than men. Since 2007 prevalence of 
sedatives or tranquillisers has increased 
among women and men. The extent 
of the increase was similar for last year 
rates but for lifetime rates the change 
was larger among men.
n In 2011 women were more likely to 
report taking anti-depressants than 
men. Since the survey in 2007 lifetime 
prevalence for men increased while  
no change was found for women.
n Use of sedatives or tranquillisers 
continues to be higher among older 
(35–64 yrs) than younger (15–34) 
adults. Since 2007 prevalence 
increased for both age groups. 
However younger adults in 2011 were 
more likely to report use of sedatives/
tranquillisers on a lifetime and last 
year basis when compared to younger 
adults in 2007.
n Use of anti-depressants was higher 
among older (35–64 yrs) than younger 
(15–34) adults in 2011. Since the 
2007 survey the proportion of older 
adults reporting lifetime use of anti-
depressants has increased.
n The average age at which respondents 
first took sedatives or tranquillisers in 
Ireland is 30 years. Age of first use 
of sedatives or tranquillisers is lower 
among men (28 years) than women 
(30 years) in 2011.
n The average age at which respondents 
first took anti-depressants is 30 years, 
2 years earlier than the age of first use 
reported in 2007. Age of first use is 
lower among women (30 years) than 
men (34 years).
n More than half (53%) of respondents 
who take sedatives or tranquillisers 
reported doing so on 20 or more  
of the 30 days before the survey.
n Most (92%) respondents who take 
anti-depressants reported doing so  
on 20 or more of the 30 days before 
the survey.
n Prescription was the main way that 
people said they access sedatives or 
tranquillisers (95%) and is also the 
main method used to access anti-
depressants (98%). For both sedatives 
or tranquillisers and anti-depressants, 
the share of people who purchased 
the drugs without prescription from 
a chemist or who got them from 
someone they know has declined  
since 2007.
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n For sedatives or tranquillisers and 
anti-depressants, prevalence rates are 
highest among people in professional 
and higher managerial positions 
and among people who are State 
dependent.
n Prevalence of sedatives or 
tranquillisers and anti-depressants 
are also associated with other 
indicators of deprivation: prevalence 
of sedatives or tranquillisers and of 
anti-depressants are highest among 
those who are not in paid work and 
those who live in local authority/
social housing. Prevalence of anti-
depressants is highest among those 
who ceased education at 15 years  
or under.
Northern Ireland  
Key Findings
n The results from the 2010/11 survey 
show that the prevalence rates for 
sedatives or tranquillisers for adults 
aged 15–64 in Northern Ireland 
were 21% (lifetime), 11% (last year) 
and 8% (last month). Since 2006/7 
there were no significant differences 
for lifetime, last year and last month 
prevalence.
n There were no significant differences 
for sedatives or tranquillisers 
between 2006/7 and 2010/11 for 
the categories of all adults, males, 
females, young adults (15–34 yrs) 
and older adults (35–64 yrs) for any 
of the prevalence rates.
n For anti-depressants, prevalence rates 
among adults aged 15–64 years 
were 22% (lifetime), 12% (last year) 
and 10% (last month). Significant 
increases were found between 
2006/7 and 2010/11 for last year 
and last month prevalence rates for 
all adults, males and older adults 
(35–64 yrs).
n Prevalence rates were higher for 
older respondents (35–64 yrs) than 
younger respondents (15–34 yrs) 
for both tranquillisers or sedatives 
and anti-depressants. For each 
of these drug categories, results 
were significantly higher for older 
respondents for all prevalence 
periods.
n In relation to sedatives or 
tranquillisers, females reported  
higher significant prevalence rates 
than males for lifetime prevalence 
and last year prevalence.
n There were significant differences 
between males and females for 
all three prevalence rates for anti-
depressants, females having higher 
prevalence rates than males.
n The average (median) age that 
respondents reported they had first 
used sedatives or tranquillisers was 
32 years – 31 years for males and  
32 years for females.
n With regards to sedatives or 
tranquillisers, there was a significant 
change between 2006/7 and 
2010/11 in relation to the average 
(median) age of first use in young 
adults (15–34 yrs).
n The average (median) age that 
respondents reported they had first 
used anti-depressants was 32 years – 
35 years for males and 32 years for 
females.
n Over two-thirds (69%) of current 
users of sedatives or tranquillisers and 
over nine in ten (94%) current users 
of anti-depressants took them daily or 
almost daily.
n The vast majority of current users took 
sedatives or tranquillisers (99%) and 
anti-depressants (99%) orally.
n Most current users got their sedatives 
or tranquillisers (95%) or their anti-
depressants (99%), on prescription.
n Respondents who were divorced, 
widowed or separated reported high 
prevalence rates for sedatives or 
tranquillisers and anti-depressants.
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Introduction
The survey was commissioned by the National Advisory 
Committee on Drugs (NACD) in Ireland and the Public Health 
Information & Research Branch (PHIRB) within the Department 
of Health, Social Services and Public Safety (DHSSPS) in 
Northern Ireland.
The main purpose of the survey was to obtain prevalence rates 
for key illegal drugs, such as cannabis and cocaine on a lifetime 
(ever used), last year (recent use) and last month (current use) 
basis. The survey also covers prescription drugs including sedatives 
or tranquillisers and anti-depressants. Similar prevalence questions 
were asked for alcohol, tobacco and other drugs.
About the Drug Prevalence Survey
The questionnaire and methodology for the general population 
survey were based on best practice guidelines drawn up by 
the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). The questionnaires were administered through face-
to-face interviews with respondents aged between 15 and 64 
years and who are normally resident in households in Ireland 
and Northern Ireland. Thus persons outside these age ranges, or 
who do not normally live in private households, have not been 
included in the survey (for example prisons, nursing homes etc).
Fieldwork for the survey was carried out between October 2010 
and May 2011 and the final achieved sample comprised 7,669 
respondents (5,134 in Ireland and 2,535 in Northern Ireland). 
Interviews were conducted using computer-assisted personal 
interviewing (CAPI). These techniques allow interviews to be 
conducted more efficiently and more accurately than other 
techniques such as pen-and-paper completion.
The response rate for the survey was 60% in Ireland and 67% 
in Northern Ireland. Area based sampling was applied in Ireland. 
The first stage involved stratifying by Health Board in Ireland1. 
The achieved sample was weighted by gender, age and region2 
in Ireland and by gender, age and Health and Social Care Trust 
area in Northern Ireland3 to maximise its representativeness of 
the general population.
Details of the methodology have been summarised in a paper 
published on the websites of the NACD (http://www.nacd.ie/) 
and the DHSSPS (http://www.dhsspsni.gov.uk/).
What is Prevalence?
The term prevalence refers to the proportion of  
a population who have used a drug over a particular  
time period. In general population surveys prevalence  
is measured by asking respondents in a representative 
sample drawn from the population to recall their use of 
drugs. The three most widely used recall periods are: 
lifetime (ever used a drug), last year (used a drug in the  
last twelve months) and last month (used a drug in the last 
30 days). Provided that a sample is representative of the 
total population, prevalence information obtained from a 
sample can be used to infer prevalence in the population.
Lifetime prevalence refers to the proportion of the sample 
that reported ever having used the named drug at the 
time they were surveyed. A person who records lifetime 
prevalence may or may not be currently using the drug. 
Lifetime prevalence should not be interpreted as meaning 
that people have necessarily used a drug over a long period 
of time or that they will use the drug in future.
Last year prevalence refers to the proportion of the 
sample that reported using a named drug in the year prior 
to the survey. Last year prevalence is often referred to as 
recent use.
Last month prevalence refers to the proportion of the 
sample that reported using a named drug in the 30 day 
period prior to the survey. Last month prevalence is often 
referred to as current use. A proportion of those reporting 
current use may be occasional (or first-time) users who 
happen to have used in the period leading up to the survey  
– it should therefore be noted that current use is not 
synonymous with regular use.
As with other European surveys, people over the age of 64  
are excluded from this survey, as they grew up in an era 
when both the use and availability of illegal drugs were very 
limited. Therefore surveys with older people have, to date, 
shown very low rates of use even on a lifetime basis. This 
situation will change over time as the younger population 
grows older. Hence lifetime prevalence rates are likely to 
increase for a considerable period of time. When examining 
the data and comparing results over time, last year use is  
the best reflection of changes as it refers to recent use. Last 
month use is equally valuable as it refers to current use.
1 Since January 2005 the Health Boards in Ireland have been restructured and merged under one authority, the Health Service Executive. For the purpose of 
facilitating comparisons between the 2002/3, 2006/7 and the current survey, it was decided to continue to weight the data by the former Health Board areas  
as these correspond with the Regional Drug Task Force (RDTF) structures.
2 The composition of the population in Ireland changed substantially since Census 2006. Given that Census 2011 information was not available when weights 
were calculated, data were weighted using 2010 population estimates. For the purpose of constructing post-stratification weights, Regional Authority areas were 
used to define regions instead of Health Board/RDTF.
3 Since the 2006/7 Survey the Health and Social Services Boards and the Health and Social Care Trusts have been restructured. In the 2010/11 survey the data 
have been weighted by the five Health and Social Care Trust areas, while in the previous two surveys the data was weighted by the four Health and Social 
Services Boards that existed at the time.
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Understanding the Results of  
this Bulletin
Results from the three NACD Drug Prevalence Surveys 
(November 2011) were published in the first 2011 bulletin First 
Results from the 2010/11 Drug Prevalence Survey and gave 
lifetime, last year and last month prevalence rates for key drugs 
for the Island of Ireland, Republic of Ireland and Northern Ireland. 
The second bulletin (June 2012) Results for Regional Drug Task 
Force and Health and Social Care Trust, presented prevalence 
rates at a regional level for Ireland and Northern Ireland.
Presentation of Estimates
This bulletin contains prevalence rates and other relevant 
information regarding the use of sedatives or tranquillisers and 
anti-depressants in Ireland and Northern Ireland for 2010/11. 
Results are given for all respondents (all adults aged 15–64 
years) and for gender and age (15–34 and 35–64 years) 
categories.
Comparisons between 2010/11 and 2006/7 results are 
presented for prevalence and age of first use. In the 2010/11 
and 2006/7 surveys, respondents were asked about use of 
sedative and tranquillisers in one question and about anti-
depressants in a separate question. This was a change from 
practice in the survey in 2002/3 when respondents were asked 
about use of sedatives, tranquillisers or anti-depressants together. 
As a result of these measurement changes comparisons 
between 2010/11 and 2006/7 only are available.
Statistical significance tests for changes over time have been 
undertaken and changes that reach the threshold for statistical 
significance have been included in reporting (for further details 
see below). The figures for Ireland in 2006/7 reported in 
this bulletin may differ slightly from figures reported in earlier 
publications. These differences are due to applying improved 
estimation procedures for comparing between 2006/7 and 
2010/11 drug prevalence survey data.
All prevalence rates presented in the accompanying tables 
are rounded to one decimal place and are rounded to whole 
numbers in the text. Where it provides for a better understanding 
of the situation, figures are sometimes reported in the text at 
one decimal place (e.g. small/low figures).
Invalid responses have been excluded from all analyses. 
Percentages may not always sum to 100 due to either the effect 
of rounding or where respondents could give more than one 
answer.
Reliability of Estimates
Effects of Survey design and statistical significance: 
The vast majority of surveys employ complex design features 
including stratification and clustering as well as weighting 
adjustments. These features greatly improve the efficiency  
and coverage of the survey but their effects must be taken 
into account in data analysis and estimation. The analyses for 
the 2011 NACD bulletins/reports incorporate these effects and 
are addressed in three key ways: (i) The confidence intervals 
for prevalence estimates are design effect adjusted using the 
Clopper Pearson method; (ii) For the change in prevalence over 
time, significance levels are calculated on the basis of design-
effect adjusted Newcombe-Wilson Hybrid Confidence Intervals; 
(iii) Ordinal and non-normally distributed metric outcomes are 
modelled in an ordinal regression framework with Wald F-Test 
as significance test. This is the equivalent of a Mann-Whitney-
Wilcoxon test for complex surveys4; (iv) Similarly, the significance 
of associations between prevalence rates and multi-categorical 
grouping variables is tested by Wald F-Tests for logistic regression 
models.
The tests of statistical significance are used to establish the 
degree of confidence with which we can infer that the observed 
changes in drug prevalence between 2010/11 and 2006/7 are 
not due to sampling error. For the change in prevalence over 
time, a significance level of 5% has been specified which means 
that the likelihood that sampling error accounts for the observed 
change is less than 5%. More stringent criteria are used for the 
tests of association for instance between prevalence and socio-
economic group: for these significance levels of 1% and 0.1% 
are used. For greater transparency the actual significance level 
p rather than the threshold value is reported when discussing 
results of tests of association.
In statistical testing, a result is deemed statistically significant  
if it is unlikely to have occurred by chance and hence provides 
enough evidence to reject the hypothesis of ‘no effect’. As used 
in statistics, significant does not mean important or meaningful, 
as it does in everyday speech. It is important to realise that 
statistical significance and substantive or practical significance 
are not the same. A small, but important, real-world difference 
may fail to reach significance in a statistical test. Conversely, a 
statistically significant finding may have no practical consequence. 
This is especially important to remember when working with 
large sample sizes because any difference can be statistically 
significant if the samples are extremely large. Whether the 
change is of practical importance is reflected in an evaluation  
of effect size, which is a substantive issue.
4 Natarajan S, Lipsitz S, Fitzmaurice GM, Sinha D, Ibrahim JG, Haas J, Gellad W, An extension of the Wilcoxon rank sum test for complex sample survey data, 
Journal of the Royal Statistical Society, Applied Statistics (2012), 61/4: 653–644.
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Robustness: Sometimes bivariate association can be 
confounded by other variables most notably gender and age. 
Where this is the case in the reporting of Republic of Ireland 
data, it is noted in the text and findings that are not robust are 
not included in the key findings section.
Limitations of the General Population  
Survey Methodology
A general population drug prevalence survey has some 
limitations. As mentioned earlier, some groups with high drug 
use prevalence are not covered by the general population 
survey method (for example the homeless, those in prison). 
Additionally, drug prevalence questions are considered to be 
sensitive and therefore people may refuse to participate or they 
may under-report their drug use. Moreover, for some groups the 
numbers can be too small for reliable prevalence estimations 
and for these specific groups, general population prevalence 
estimates can be supplemented by other methods (e.g. capture-
recapture for problem drug use and surveys targeting special 
populations (e.g. prisoners, students, early school leavers).
In order to assess reliability of the drug prevalence estimates, 
95% confidence intervals have been calculated and are available 
on the NACD website.
Glossary
Sedatives and Tranquillisers
Sedatives and tranquillisers are commonly used terms for 
the same group of medicines which depress, slow down or 
calm the brain and central nervous system. They are mainly 
Benzodiazepines (“Benzos”) but other drugs with the same 
effects e.g. Zolpidem and Zopiclone are included in this group. 
Medically they are often referred to as hypnotics, which induce 
sleep and anxiolytics or anti-anxiety agents.
The same drug can be used as a hypnotic or as an anti-anxiety 
agent depending on the dosage used and on the time of day 
that they are used. Hypnotics are used to treat insomnia (lack 
of adequate restful sleep) which is causing distress. Anxiolytics 
are often referred to as ‘minor tranquillisers’. Benzodiazepines 
anxiolytics are the most common type used to obtain relief of 
severe and disabling anxiety.
Anti-depressants
These are medicines used to treat conditions such as the low or 
sad mood, loss of interest or pleasure in daily activities, fatigue 
and energy loss usually known as depression. Different drug 
classes are available on prescription to treat depression. All of 
these drugs above are prescribed under medical supervision  
and can only be obtained by description from a pharmacist.
Socio-economic Grouping
In the Republic of Ireland socio-economic grouping is based 
on a classification of occupation and coded to the Standard 
Occupation Classification 2000.
SOC2000 Classification
A Professionals, senior management and top civil servants
B Middle management, senior civil servants, managers and 
owners of business
C1 Junior management and owners of small businesses
C2 Skilled manual workers and manual workers responsible 
for other workers
D Semi-skilled and unskilled manual workers, trainees and 
apprentices
E All those dependent on the State long-term
Respondents were coded into the following social grades in 
Northern Ireland based on the National Statistics Socio-Economic 
Classification (NSSEC). The NSSEC classification data shown in 
Table 21 relate to the individual.
NSSEC Classification
n Managerial and professional occupations
n Intermediate occupations
n Small employers and own account workers
n Lower supervisory and technical occupations
n Semi-routine and routine occupations
n Never worked and long-term unemployed
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Results – Ireland
Prevalence Rates and Comparisons between 
2006/7 and 2010/11
Sedatives or Tranquillisers (Table 1a)
The results from the 2010/11 survey show that for adults aged 
15–64 the prevalence rates for sedatives/tranquillisers in Ireland 
are 14% (lifetime), 7% (last year) and 3% (last month). Since 
the last survey in 2007, lifetime prevalence of sedatives or 
tranquillisers increased (+3.4 percentage points) and last year 
prevalence also increased (+1.8 percentage points) among all 
adults in Ireland.
Anti-depressants (Table 1b)
For anti-depressants, prevalence rates among adults aged 15–64 
years are 10% (lifetime), 5% (last year) and 4% (last month). 
Lifetime and last year prevalence have changed little since the 
last survey. The only change found to be statistically significant 
was an increase of just under 1 percentage point in last month 
prevalence of anti-depressants (all adults; 15–64 yrs).
Gender
Sedatives or Tranquillisers (Table 1a)
Prevalence of sedatives or tranquillisers is higher among women 
than men for lifetime (16% vs 12%), last year (7% vs 6%) 
and last month (5% vs 3%) use. The results show that the 
difference between men and women’s use in 2010/11 is 
statistically significant for all three prevalence measures.
Changes in prevalence of sedatives or tranquillisers were found 
for men and women since the last survey. The results show 
increased lifetime rates among men (+4.4 percentage points) 
and women (+2.3 percentage points) and increased last year 
rates among men (+2.0 percentage points) and women (+1.6 
percentage points). Since the last survey there was no other 
statistically significant change.
Anti-depressants (Table 1b)
Use of anti-depressants in 2011 is higher among women than 
men for lifetime (13% vs 8%), last year (6% vs 4%) and last 
month (5% vs 3%) measures. The difference between men and 
women’s lifetime, last year and last month use in 2010/11 is 
statistically significant.
Rates for men’s lifetime use of anti-depressants increased (+2.4 
percentage points) between 2007 and 2011 while no statistically 
significant changes are recorded among women for that period.
Age
Sedatives or Tranquillisers (Table 1a)
Results from the 2010/11 survey show that the prevalence of 
sedatives or tranquillisers is higher among older (35–64 yrs) 
than younger (15–34 yrs) adults as shown in lifetime (17% vs 
10%), last year (8% vs 5%) and last month (4% vs 1%) rates.
Since the survey in 2007 there have been increases in lifetime 
prevalence of sedatives or tranquillisers among younger and 
older adults. The increase was larger among younger (+4.2 
percentage points) than older adults (+2.3 percentage points). 
Compared to 2007, younger adults in 2011 are more likely 
to report last year use of sedatives and tranquilisers (+2.3 
percentage points).
Anti-depressants (Table 1b)
Table 1b shows that use of anti-depressants is higher among 
older (35–64 yrs) than younger (15–34 yrs) adults as shown 
in lifetime (13% vs 7%), last year (6% vs 3%) and last month 
(6% vs 2%) rates.
Lifetime use of anti-depressants among older adults has increased 
(+2.3% percentage points) since the last survey in 2007.
Age of First Use
Sedatives or Tranquillisers (Table 2a)
Table 2a shows that among all adults (15–64 yrs) the median 
age of first use of sedatives or tranquillisers in 2011 is 30 years. 
Although the median age for all adults in 2007 was also 30 
years, statistical analyses shows that median age of first use 
tends to be higher in 2011 when compared to 2007 (p=.025)5.
Among men the median age is lower (28 years) than among 
women (30 years). Younger adults (15–34 yrs) began using 
sedatives or tranquillisers much earlier (22 years) than older 
adults (37 years). Age of first use for older adults in 2011 
(37 years) is slightly higher than in 2007 (35 years). There is 
no change since 2007 in the median age of first use among 
younger adults.
Anti-depressants (Table 2b)
Table 2b shows that among all adults the median age of first 
use of anti-depressants is 30 years, two years lower than the 
median age recorded in 2007. Age of first use is lower among 
women (30 years) than men (34 years) and lower among 
younger adults (21 years) than older adults (35 years). However 
the distribution of median age at first use of anti-depressants in 
Ireland between 2007 and 2011 has not changed in a way that 
was statistically significant.
5 The Mann-Whitney-Wilcoxon tests are rank sum tests and not median tests. The Mann-Whitney-Wilcoxon tests rank all of the observations from both groups and 
then sums the ranks from one of the groups which is compared with the expected rank sum. It is possible, although not very common, for groups to have 
different rank sums and yet have equal or nearly equal medians.
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Frequency of Use
Sedatives or Tranquillisers (Table 3a)
Table 3a shows that of those currently using sedatives or 
tranquillisers, more than half (53%) reported taking them on 20 
or more of the 30 days before the survey (highest frequency use 
category). Since 2007 there has been a decline (-3.8 percentage 
points) in the share reporting the highest frequency use category 
and an increase in the share reporting the other frequency use 
categories.
Women are marginally more likely than men to report the high 
frequency use category in 2011 (54% vs 53%). This marks a 
change from 2007 when high frequency use was substantially 
higher among women. The narrowing between women and 
men’s propensity for high frequency use is mainly due to the 
lower share of women (-6.2 percentage points) reporting high 
frequency use in 2011 when compared to 2007.
Table 3a shows that older adults (35–64 yrs) are more likely 
than younger adults (15–34 yrs) to report high frequency use of 
sedatives or tranquillisers in 2011 (59% vs 23%). However the 
greater propensity to report high frequency in 2011 is due largely 
to the decline among younger adults (-18.7 percentage points) 
reporting high frequency use of sedatives or tranquillisers since 
the last survey6.
Anti-depressants (Table 3b)
Of those who currently take anti-depressants, the vast majority 
(92%) reported using them on 20 or more of the 30 days 
before the survey. The 2011 results show that women (94%) 
are more likely to report high frequency use of anti-depressants 
than men (90%). Rates are very similar for younger (15–34 yrs) 
and older (35–64 yrs) adults (92% vs 93%).
Method of Taking Sedatives or Tranquillisers 
and Anti-depressants (Table 4)
Sedatives or Tranquillisers
The results presented in Table 4 show that of those who 
currently take sedatives or tranquillisers the majority (98%) take 
them in oral form (i.e. tablets or syrup). Women are marginally 
more likely than men to report this method (99% vs 98%) 
and the rates are the same for younger (15–34 yrs) and older 
(35–64 yrs) adults (98% for both age groups). Just less than 
2% of current users reported injecting sedatives or tranquillisers 
in 2011.
Anti-depressants
Of current users an overwhelming majority (100%) said they 
consumed anti-depressants in oral form (tablets or syrup)  
(Table 4).
How Sedatives or Tranquillisers and  
Anti-depressants were Obtained (Table 5)
Sedatives or Tranquillisers
Results (Table 5) show that the most common way current users 
obtain sedatives or tranquillisers is by prescription: Compared 
with women (93%), men (98%) are more likely to get sedatives 
or tranquillisers on prescription and older adults (96%) are more 
likely than younger adults (90%) to do so.
A relatively small share (3%) said they bought sedatives or 
tranquillisers without prescription in a chemist and this response 
was more common among women (4%) than men (1%) and 
more common among older (3%) than younger (0%) adults.
Of current users, 2% obtain sedatives or tranquillisers from 
someone they know. Younger adults are more likely than older 
adults to report this (10% vs 1%): this is a large change in the 
age group profiles reporting this method in 2007 (13% and 
6%). No respondents reported using the internet to purchase 
sedatives or tranquilisers and this is unchanged since 2007.
Anti-depressants
Among people currently taking anti-depressants in Ireland the 
most common method is by prescription (98%). Women and 
men are almost equally likely to report this method (98% vs 
97%) while a greater share of older adults (99%) than younger 
adults (95%) reported using prescription. A far smaller share 
reported buying anti-depressants without a prescription from a 
chemist (2%). Compared to women, men were more likely to 
buy without prescription from a chemist (3% vs 1%) and this 
response was also more likely among younger (3%) than older 
adults (1%). No respondents reported using the internet to 
purchase anti-depressants and this is unchanged since 20077.
6 The number of young adults (15–34 yrs) who are current users of sedatives or tranquillisers in this survey sample is very small. It should be noted that the 
precision of the estimates for frequency of use is affected by this small number. For this reason points estimates should be interpreted with caution.
7 These figures for 2007 are not reported in Table 5. For further information please see NACD Bulletin 6 Drug Use in Ireland and Northern Ireland: 2006/2007 
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User profile
Sedatives or Tranquillisers and Anti-
depressants Prevalence by Socio-economic 
Group (SOC2000 Classification) (Table 6)
Sedatives or Tranquillisers
Table 6 shows the prevalence for sedatives or tranquillisers 
in 2011 broken down by socio-economic group. The results 
show that prevalence is highest among Groups E (All those 
dependent on the state long-term) and A (Professionals, Senior 
management and top civil servants). For Group E prevalence 
rates are 19% (lifetime), 11% (last year) and 7% (last month). 
Group A prevalence rates are 18% (lifetime), 11% (last year) 
and 3% (last month). In comparison lifetime and last year rates 
are lower in the remaining groups (Groups B-D). The association 
between the prevalence of sedatives or tranquillisers and socio-
economic group is statistically significant (p=.000) for each 
prevalence measure.
Anti-depressants
Table 6 shows that people in Group E in Ireland (All those 
dependent on the state long-term) are most likely to report 
use of anti-depressants. Prevalence rates for anti-depressants 
for Group E are 19% for lifetime, 10% for last year and 9% 
for last month use. In contrast Group A (Professionals, Senior 
Management and top Civil Servants) is least likely to use anti-
depressants: prevalence rates for Group A are 8% for lifetime, 
2% for last year and 2% for last month use. The association 
between prevalence of anti-depressants and socio-economic 
group is statistically significant (p=.000).
Work Status (Table 7)
Sedatives or Tranquillisers
Table 7 presents 2011 results for prevalence of sedatives or 
tranquillisers according to the work status of survey respondents. 
These results show that prevalence of sedatives or tranquillisers 
in 2011 is highest among those not in paid work and for this 
group prevalence rates are 19% (lifetime), 11% (last year)  
and 7% (last month).
For the remaining groups, lifetime rates for sedatives or 
tranquillisers are higher among those in paid work (13%) than 
among students (10%). Last year prevalence is the same for 
students and people in paid work (6% for both) while last 
month rates are slightly higher for students (3% vs 2%). This 
pattern is supported by statistically significant results for each  
of the prevalence measures (p=.000).
Anti-depressants
Results in Table 7 outline the association between use of anti-
depressants and respondents’ work status. The results show  
that people who are not in paid work are most likely to use  
anti-depressants in 2011: For this group prevalence rates for  
anti-depressants are 17% (lifetime) 10% (last year) and 8% 
(last month). Lower 2011 prevalence rates are found for those 
who are in paid work: 9% (lifetime), 4% (last year) and 3% 
(last month). Of the three groups the lowest rates for anti-
depressant use are among students: lifetime (9%), last year 
(3%) and last month (less than 1%). The association between 
prevalence of anti-depressants and work status is statistically 
significant (p=.000).
Housing Tenure (Table 8)
Sedatives or Tranquillisers
Table 8 sets out prevalence of sedatives or tranquillisers 
according to different types of housing tenure. For all prevalence 
types, the rates for sedatives or tranquillisers are highest for the 
group that is ‘Renting from local authority/housing agent’: For 
this group rates are 20% (lifetime), 10% (last year) and 6% 
(last month). The group next most likely to use sedatives or 
tranquillisers are those who own property (in part or full): Table 
8 shows that prevalence rates for this group are 14% (lifetime), 
7% (last year) and 3% (last month). Prevalence of sedatives 
or tranquillisers in Ireland is lowest among those renting from a 
private landlord, followed by the ‘other’ category. The association 
between prevalence of sedatives or tranquillisers and housing 
tenure is statistically significant (p=.000).
Anti-depressants
Table 8 also outlines prevalence of anti-depressants in Ireland 
in 2011 according to different types of housing tenure. The 
results shows that use of anti-depressants is highest among 
those who are renting from local authority/housing agent and 
the prevalence rates are 22% (lifetime), 12% (last year) and 
11% (last month). Rates are lower for those who own property 
(in part or in full) at 10% (lifetime), 4% (last year) and 4% 
(also for last month). The association between prevalence of 
anti-depressants and housing tenure is statistically significant 
(p=.000).
Age Ceased Education (Table 9)
Sedatives or Tranquillisers
Table 9 outlines the prevalence of sedatives or tranquillisers 
according to age at which people ceased formal education. 
The results show that prevalence of sedatives or tranquillisers 
is highest among those who left school earliest (15 years and 
under). For this group rates are 20% (lifetime), 10% (last year) 
and 7% (last month). For those who ceased education between 
16–19 years prevalence rates are 14% (lifetime), 7% (last year) 
and 4% last month. These are similar to those who ceased 
education at 20 years and older: 15% (lifetime), 7% (last year) 
and 2% (last month). The association between prevalence of 
sedatives or tranquillisers and aged ceased formal education is 
statistically significant (p=.000).
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Anti-depressants
Table 9 outlines the prevalence of anti-depressants by the age 
respondents ceased their formal education. The pattern of 
results shows use of anti-depressants decreases with number of 
years in education. Those who left school earliest (15 years and 
under) are most likely to use anti-depressants (p=.000). The 
prevalence rates for those who left school at 15 years or under 
are: 19% (lifetime), 10% (last year) and 9% (last month).
The lifetime rates for anti-depressants among those who left 
school at 16–19 years are the same as the rates for those who 
left at 20 years and over (11% for both) while last year and 
last month rates are slightly higher for those who left school at 
16–19 years: last year (6% vs 4%) and last month (5% vs 3%).
Highest Qualification Level Attained  
(Table 10)
Sedatives or Tranquillisers
Table 10 presents prevalence of sedatives or tranquillisers 
according to respondents’ highest level of qualification. Lifetime 
rates are highest for those with third level education at 16%. In 
contrast the other prevalence rates were highest for those with 
primary education at 7% (last year) and 5% (last month). The 
association between prevalence of sedatives or tranquillisers and 
level of qualification is statistically significant (p=.000).
Anti-depressants
Table 10 presents prevalence of anti-depressants by highest 
level of qualification attained. The results for 2011 show that 
use of anti-depressants is highest among those who attained 
primary level as their highest qualification level: Lifetime rate for 
this group is 12% while for those with upper secondary and 
third level qualifications, lifetime rates are about 10% (each). 
Last year anti-depressant use is 7% for those with primary as 
their highest qualification level; again higher than the rate for 
those who attained secondary or third level qualifications (5% 
each). Finally last month prevalence for those whose highest 
qualification attained is primary level is 6%, lower than the  
other qualification level groups (about 4% for each group).
The differences with regard to use of anti-depressants between 
those with primary and those with higher levels of education 
completed are not statistically significant.
Marital Status (Table 11)
Sedatives or Tranquillisers
Table 11 sets out 2011 prevalence for sedatives or tranquillisers 
according to survey respondents’ marital status. About one 
quarter of those classified as widowed, divorced and separated 
reported taking sedatives or tranquillisers on a lifetime basis 
(29%, 25% and 24%). Last year rates were also highest for 
these groups (15%, 17% and 11%) as are last month rates 
(11%, 12% and 8%).
Rates for sedatives or tranquillisers are higher among married 
than single people for lifetime (14% vs 11%) and last month 
(3% vs 2%) measures. However once the effects of age and 
gender are controlled8, single people are significantly more 
likely to use sedatives or tranquillisers than married people on a 
lifetime (p=.000), last year (p=.001) and last month (p=.012).
Comparing cohabiting and married groups, lifetime rates are 
slightly higher among those co-habiting than married (16% vs 
14%); last year rates are also higher among the cohabiting than 
married (8% vs 6%) groups. Table 11 shows that last month 
prevalence of sedatives or tranquillisers is lower among married 
people (2.9% vs 2.0%). The association between prevalence 
of sedatives or tranquillisers and marital status is statistically 
significant (p=.000).
Anti-depressants
Table 11 sets out 2011 prevalence for anti-depressants by 
marital status. Prevalence is highest among respondents who 
are divorced and the rates are lifetime (26%), last year (15%) 
and last month (12%). Prevalence rates for anti-depressants are 
lowest among those who are single: lifetime (11%), last year 
(6%) and last month (2%). The pattern of results for prevalence 
of anti-depressants is statistically significant for all prevalence 
measures (p=.000).
Rates among married people are higher than those for single 
people and this applies to lifetime (11% vs 8%), last year (5% 
vs 4%) and last month (4% vs 3%). However once the effects 
of age and gender are controlled8, results show that single 
people are significantly more likely than married people to take 
anti-depressants (p=.000) and this holds for lifetime, last year 
and last month prevalence measures.
8 The results controlled for age and gender effects are not reported in the tables of this bulletin.
Drug use in Ireland and Northern Ireland: 2010/11 Drug Prevalence Survey:  
Sedatives or Tranquillisers and Anti-depressants Results
11National Advisory Committee on Drugs (2012)
Results – Northern Ireland
Age
Sedatives or Tranquillisers (Table 14a)
In 2010/11, over one in five respondents (21%) aged 15–64 
reported that they had used sedatives or tranquillisers at some 
point in their lives, 11% had used them in the last year and 8% 
had used them in the last month.
There were no significant differences between 2006/7 and 
2010/11 in relation to the categories of all adults, males, 
females, young adults (15–34 yrs) and older adults (35–64 yrs), 
for any of the prevalence rates.
Anti-depressants (Table 14b)
Over one fifth (22%) of all adults in 2010/11 reported lifetime 
use of anti-depressants, 12% had used them in the last year and 
10% had used them in the last month.
Last year prevalence between all adults was statistically 
significant between 2006/7 and 2010/11 – an increase of 2.9 
percentage points. Significant increases were also found for male 
respondents (+3.1 percentage points) and in relation to older 
adults (35–64 yrs) (+4.0 percentage points).
There were significant differences in relation to last month 
prevalence rates between 2006/7 and 2010/11. These were 
found between all adults (+2.7 percentage points), males  
(+3.4 percentage points) and older adults (+4.0 percentage 
points).
There were no significant differences between 2006/7 and 
2010/11 for the categories of all adults, males, females, young 
adults (15–34 yrs) and older adults (35–64 yrs) for lifetime 
prevalence.
Age of First Use
Sedatives or Tranquillisers (Table 15a)
The average (median) age9 that all adults reported they had  
first used sedatives or tranquillisers was 32 years in 2010/11 
– 32 years for females and 31 years for males. Young adults 
(15–34 yrs), on average reported first using these drugs at 20 
years, while older adults (35–64 yrs), on average reported first 
using these drugs at 38 years.
There was a significant difference in relation to the age that 
young adults had first taken sedatives or tranquillisers between 
2006/7 and 2010/11 (p=0.049). However, this figure is close 
to the 0.05 level of significance and caution should be exercised 
here as this may result in a Type I error (i.e. when the null 
hypothesis has been rejected when there is in fact no difference 
in the samples between 2006/7 and 2010/11). Conversely, 
although there was no difference between males for the years 
2006/7 and 2010/11 the probability (p=0.054) is also close to 
the 0.05 level of significance and there is therefore the potential 
of creating a Type II error (i.e. rejecting the null hypothesis when 
it is false).
There were no significant differences in relation to all adults, 
females and older adults between 2006/7 and 2010/11.
Anti-depressants (Table 15b)
In 2010/11, the average age that respondents aged 15–64 
years reported they had first used anti-depressants was 32 
years; the corresponding age for males was 35 years and the 
corresponding age for females was 32 years. Young adults  
(15–34 yrs) reported first having used anti-depressants at  
20 years while older adults (35–64 yrs) reported first using 
these at 37 years.
There were no significant differences in relation to all adults, 
males, females, young adults or older adults (35–64 yrs), 
between 2006/7 and 2010/11.
Frequency of Use
Sedatives or Tranquillisers (Table 16a)
Over two thirds (69%) of current users aged 15–64 reported 
that they used sedatives or tranquillisers on a daily or almost 
daily basis. The proportions for males and females were 70% 
and 69% respectively. Older adults (35–64 years) were more 
likely to use tranquillisers or sedatives on a daily basis than 
younger adults (15–34 years) – 73% compared with 55%.
There were no significant differences in relation to frequency  
of use for all adults, males, females, young adults (15–34 yrs) 
and older adults (35–64 yrs), between 2006/7 and 2010/11.
Anti-depressants (Table 16b)
Almost all (94%) current users of anti-depressants take them 
on a daily or almost daily basis. Similar proportions of females 
(94%) and males (93%) reported that this was the case.  
A higher proportion of older adults (95%) than young adults 
(89%) reported daily or almost daily consumption.
There were no significant differences in relation to frequency  
of use for all adults, males, females, young adults (15–34 yrs) 
and older adults (35–64 yrs), between 2006/7 and 2010/11.
9 The median was used to measure central tendency in the case of age of first use to avoid extreme values skewing the results.
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Method of Taking Sedatives or Tranquillisers 
and Anti-depressants (Table 17)
Sedatives or tranquillisers
Almost all (99%) current users of sedatives or tranquillisers 
reported that they took these drugs orally – 100% of females 
and 98% of males. Similar proportions of older adults (35–64 
yrs) and young adults (15–34 years) reported that this was the 
case – 99% and 100% respectively.
Anti-depressants
Almost all (99%) current users of anti-depressants did so orally 
– 100% of males and 99% of females. The proportions for 
young adults (15–34 yrs) and older adults (35–64 yrs) were 
100% and 99% respectively.
How Sedatives or Tranquillisers and  
Anti-depressants were Obtained (Table 18)
All current users of sedatives or tranquillisers and anti-
depressants were asked how they had obtained their drugs.
Sedatives or Tranquillisers
The vast majority (95%) of current users of sedatives and 
tranquillisers had got them on prescription. A further 3% had 
got these from someone they knew and 2% bought these 
from a chemist without a prescription. No current sedative or 
tranquilliser user reported buying these over the internet. A 
higher proportion of females (97%) than males (93%) got 
tranquillisers or sedatives on prescription. A higher proportion 
of older adults (35–64 yrs) than younger adults (15–34 yrs) 
got these drugs on prescription – 98% compared with 83%. 
No older adults reported getting sedatives or tranquillisers from 
someone they knew, while 14% of young adults reported that 
this was the case.
Anti-depressants
Almost all (99%) current users of anti-depressants got them 
on prescription, 0.3% got them from someone they knew 
and 1% bought them over the counter in a chemist without a 
prescription. No current user reported buying anti-depressants 
over the internet. All males got their anti-depressants on 
prescription and 98% of female current users reported that 
this was the case. Almost 100% of older adults (35–64 yrs) 
and 95% of young adults (15–34 yrs) reported getting anti-
depressants on prescription. Four percent of young adults 
reported buying anti-depressants in a chemist without a 




Females had higher prevalence rates than males for all 
prevalence periods. For lifetime prevalence, this was 24% for 
females compared with 17% for males; the last year prevalence 
rate was 13% for females and 9% for males; and the last month 
prevalence rate was 9% for females and 7% for males.
There were significant differences between males and females 
for lifetime prevalence and last year prevalence.
Anti-depressants
Females reported higher prevalence rates than males for lifetime 
(28% vs 15%), last year (15% vs 9%) and last month (13% vs 
8%) prevalence rates.
There were significant differences between males and females 
for all prevalence periods.
Age (Table 20)
Sedatives or Tranquillisers
The lifetime prevalence rate for those aged 35–64 (26%) was 
almost twice that of those aged 15–34 years (14%). Older 
adults were also more than twice as likely as young adults to 
have used sedatives or tranquillisers in the last year (14% vs 
6%) and almost three times as likely to have used them in the 
last month (11% vs 4%).
There were significant differences between young adults (15–34 
yrs) and older adults (35–64 yrs) for all prevalence periods.
Anti-depressants
Similar results were found for anti-depressants, with older adults 
more likely than young adults to have used them at some point 
in their lives, in the last year and in the last month. The lifetime 
prevalence rate for those aged 35–64 (28%) was twice that of 
those aged 15–34 years (14%). Older adults had higher last 
year (16% vs 7%) and last month (14% vs 5%) prevalence 
rates than young adults.
There were significant differences between young adults (15–34 
yrs) and older adults (35–64 yrs) for all prevalence periods.
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National Statistics Socio-economic 
Classifications (NSSEC) (Table 21)
Sedatives or Tranquillisers
In relation to lifetime prevalence, there was a higher proportion 
(27%) of those who had never worked and were long-term 
unemployed using sedatives or tranquillisers, than any other 
socio-economic category. This was followed by intermediate 
occupations and semi-routine and routine occupations (both 
24%). Those classified as being small employers and own 
account workers were least likely to have used sedatives or 
tranquillisers on a lifetime basis (18%).
In terms of recent use of sedatives or tranquillisers, the highest 
prevalence rates were among those who had never worked  
and were long-term unemployed and those in semi-routine  
and routine occupations (both 15%). This was followed by  
the classification of lower supervisory and technical occupations 
(13%). In contrast, those in managerial and professional 
occupations (9%) were least likely to have used sedatives  
or tranquillisers in the last year.
Those in semi-routine and routine occupations and those who 
had never worked and were long-term unemployed (both 11%) 
had the highest last month usage of tranquillisers or sedatives. 
This was closely followed by lower supervisory and technical 
occupations (10%). Those in managerial and professional 
occupations were least likely to have used sedatives or 
tranquillisers (5%) in the last month.
The association between prevalence of sedatives or tranquillisers 
and socio-economic classification is statistically significant 
(p=0.000) at all three prevalence levels.
Anti-depressants
Approximately one third (33%) of those who had never worked 
or were long-term unemployed had taken anti-depressants at 
least once in their lives. This was followed by those in semi-
routine and routine occupations (27%). Small employers and 
own account workers (17%) were less likely than other socio-
economic groups to have lifetime prevalence of anti-depressants.
The highest last year prevalence rate for anti-depressants 
was among those who had never worked or were long-term 
unemployed (22%). This was followed by those in semi-routine 
and routine occupations (16%) and those classified as lower 
supervisory and technical occupations (13%).
Like lifetime and last year prevalence rates, those who had 
never worked or were long-term unemployed had the highest 
last month prevalence rate (17%). This was followed by those 
in semi-routine and routine occupations (14%) and those in 
intermediate occupations (10%). Those in managerial and 
professional occupations were least likely to have used anti-
depressants during the last month (8%).
The association between prevalence of anti-depressants and 
socio-economic classification is statistically significant (p=0.000) 
at all three prevalence levels.
Work Status (Table 22)
Sedatives or Tranquillisers
In relation to sedatives or tranquillisers, those not in paid 
employment had higher prevalence rates than those in paid 
employment for all three time periods – lifetime (35% vs 16%), 
last year (24% vs 6%) and last month (19% vs 3%).
Anti-depressants
This trend was also true for anti-depressants. In relation 
to lifetime prevalence this was 38% for those not in paid 
employment compared with 16% for those in paid employment. 
A quarter (25%) of those who were not in paid employment 
reported recent usage of anti-depressants compared with 7% of 
those in employment. Over one fifth (22%) of those who were 
not in paid employment had taken anti-depressants in the last 
month compared with 5% of those in paid employment.
Housing Tenure (Table 23)
Sedatives or Tranquillisers
Those who rented from a housing association (38%) and 
those who rented from the Northern Ireland Housing Executive 
(NIHE) (34%) were more likely to report lifetime prevalence 
of sedatives or tranquillisers than people living in all other types 
of housing tenure. This was also true for those who reported 
last year prevalence of sedatives or tranquillisers; 28% for those 
renting from a housing association and 21% for those renting 
from NIHE. Current users were also more likely to have rented 
from NIHE or a housing association (both 19%) than from other 
types of housing tenure.
The association between prevalence of sedatives or tranquillisers 
and housing tenure is statistically significant (p=0.000) at all 
three prevalence levels.
Anti-depressants
Over two-fifths (41%) of those respondents who rented from 
NIHE had taken anti-depressants at least once in their lifetime. 
This was followed by 35% of those who rented from a housing 
association and 24% of those who rented privately. This trend 
was also true for those who reported recent use and current use 
of anti-depressants. In relation to recent users, 28% rented from 
NIHE and 22% rented from a housing association. With regards 
to current use, 25% rented from NIHE and 16% rented from a 
housing association.
The association between prevalence of anti-depressants and 
housing tenure is statistically significant (p=0.000) at all three 
prevalence levels.
Drug use in Ireland and Northern Ireland: 2010/11 Drug Prevalence Survey:  
Sedatives or Tranquillisers and Anti-depressants Results
14 National Advisory Committee on Drugs (2012)
Education Level (Table 24)
Sedatives or Tranquillisers
Respondents who had no qualifications had higher lifetime 
(27%), last year (17%) and last month (15%) prevalence rates 
of sedatives or tranquillisers, than other respondents.
The association between prevalence of sedatives or tranquillisers 
and education level is statistically significant (p=0.000) at all 
three prevalence levels.
Anti-depressants
Persons who had no qualifications were also more likely to 
report use of anti-depressants for lifetime (29%), last year 
(18%) and last month (16%) than those with qualifications.
The association between prevalence of anti-depressants and 
education level is statistically significant (p=0.000) at all three 
prevalence levels.
Marital Status (Table 25)
Sedatives or Tranquillisers
A higher proportion of divorced, widowed and separated persons 
had taken sedatives or tranquillisers for all three time periods 
than those in other marital status categories.
The association between prevalence of sedatives or tranquillisers 
and marital status is statistically significant (p=0.000) at all three 
prevalence levels.
Anti-depressants
This trend was also found in relation to anti-depressants. A 
higher proportion of respondents who were divorced, widowed 
and separated had taken anti-depressants in all three time 
periods than those in other marital status categories.
The association between prevalence of anti-depressants and 
marital status is statistically significant (p=0.000) at all three 
prevalence levels.
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Ireland
Table 1a: Sedatives or Tranquillisers – Prevalence Rates (%)
All adults  
15–64
Males Females Young adults 
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 4967 5127 2513 2553 2454 2574 2315 2254 2652 2873
Lifetime Prevalence (Ever used) 10.5 13.9a 8.0 12.4a 13.2 15.5abc 5.9 10.1a 14.6 16.9a
Last Year Prevalence (Recent use) 4.7 6.5a 3.7 5.7a 5.7 7.3ac 2.5 4.8a 6.5 7.8
Last Month Prevalence (Current use) 3.0 2.8 2.4 2.3 3.5 3.3bc 1.3 1.0 4.4 4.1
a Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11.
b Denotes a statistically significant difference between men and women in 2006/7.
c Denotes a statistically significant difference between men and women in 2010/11.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 1b: Anti-depressants – Prevalence Rates (%)
All adults  
15–64
Males Females Young adults 
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 4967 5124 2513 2553 2454 2571 2315 2253 2652 2872
Lifetime Prevalence (Ever used) 9.2 10.4 5.9 8.3a 12.5 12.5bc 7.1 6.8 10.9 13.2a
Last Year Prevalence (Recent use) 4.3 4.8 3.0 4.0 5.6 5.6bc 3.2 3.0 5.2 6.2
Last Month Prevalence (Current use) 3.1 4.0a 2.3 3.2 3.9 5.0bc 2.2 2.3 3.9 5.5
a Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11.
b Denotes a statistically significant difference between men and women in 2006/7.
c Denotes a statistically significant difference between men and women in 2010/11.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 2a: Age of First Use of Sedatives or Tranquillisers (All Users)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 524 690 201 301 323 388 136 224 388 466
Median age of first useb 30 30a 29 28 31 30 22 22 35 37
a Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11.
b Median is used as a measure of central tendency to avoid extreme values skewing results.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
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Table 2b: Age of First Use of Anti-depressants (All Users)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 455 530 149 211 306 319 164 152 290 378
Median age of first useb 32 30 34 34 30 30 21 21 35 35
a Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11.
b Median is used as a measure of central tendency to avoid extreme values skewing results.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 3a: Frequency of Use of Sedatives or Tranquillisers per month (Current Users) (%)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 147 142 60 58 87 85 29 24 118 119
20 days or more 57.1 53.3 53.3 52.8 59.8 53.6 41.4 22.7 61.0 59.3
10–19 days 6.2 7.2 5.0 7.9 6.9 6.7 3.4 14.1 6.8 5.8
4–9 days 17.0 17.7 16.7 18.1 17.2 17.4 17.2 29.6 16.9 15.3
1–3 days 19.7 21.9 25.0 21.3 16.1 22.3 37.9 33.7 15.3 19.6
a Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11.
† Wald F-test for statistical significance (p<.001) [ordinal regression] that all groups are equal.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 3b: Frequency of Use of Anti-depressants per month (Current Users) (%)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 152 209 56 80 94 129 51 51 101 158
20 days or more 91.1 92.4 87.5 89.5 94.7 94.3 92.2 92.3 90.1 92.5
10–19 days 4.9 3.0 7.1 3.8 3.2 2.5 5.9 0.0 5.0 4.0
4–9 days 1.8 3.3 1.8 3.5 1.1 3.2 2.0 7.7 2.0 1.9
1–3 days 2.2 1.2 3.6 3.1 1.1 0.0 0.0 0.0 3.0 1.6
a Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11.
† Wald F-test for statistical significance (p<.001) [ordinal regression] that all groups are equal.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
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Table 4: Method of Taking Sedatives or Tranquillisers and Anti-depressants (Current Users) (%)



















Total Weighted N (valid responses) 142 58 85 24 119 209 80 129 51 158
Oral (Tablets or Syrup) 98.4 97.8 98.7 98.0 98.4 99.8 100 99.7 100 99.7
Injection with a Needle 1.6 2.2 1.3 2.0 1.6 0.2 0.0 0.3 0.0 0.3
Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Due to weighting, gender and/or age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 5: How Sedatives or Tranquillisers and Anti-depressants were Obtained (Current Users) (%)



















Total Weighted N (valid responses) 140 58 83 24 117 209 80 129 51 158
Got them on prescription 95.2 98.0 93.3 89.7 96.3 97.8 96.9 98.3 95.1 98.6
Got from someone I know 2.3 1.0 3.1 10.4 0.6 0.4 0.4 0.4 1.6 0.0
Bought without prescription in chemist 2.5 1.0 3.6 0.0 3.1 1.9 2.7 1.3 3.4 1.4
Bough them over the Internet 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Due to weighting, categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 6: Sedatives or Tranquillisers and Anti-depressants Prevalence by Socio-economic Group  
(SOCO2000 Classification) (%)













Total Weighted N (valid responses) 5083 5083 5083 5080 5079 5079
A. Professional, senior management, top civil servants 17.7 11.4 2.8 7.7 2.2 2.2
B. Middle management, senior civil servants, managers 
and owners of own business
13.8 5.9 2.0 9.0 4.1 3.3
C1 Junior management and owners of small business 12.9 5.2 2.0 9.2 4.1 3.4
C2. Skilled manual workers and manual workers 
responsible for other workers
12.9 5.8 2.3 8.8 3.7 3.3
D Semi-skilled and unskilled manual workers, trainees 
and apprentices
12.7 6.5 2.4 9.6 3.9 3.3
E. All those dependent on the State long-term 19.2 10.7 6.7 18.6 10.4 9.1
† Wald F-test for statistical significance (p<.001) [logistic regression] that all groups are equal.
 Due to weighting, work status categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 7: Sedatives or Tranquillisers and Anti-depressants Prevalence by Work Status (%)













Total Weighted N (valid responses) 4909 4909 4909 4907 4906 4906
In paid work 12.7 5.6 1.9 9.0 3.8 3.3
Not in paid work 18.9 10.6 6.7 17.3 9.5 8.2
Student 9.6 5.8 2.5 8.7 3.0 0.8
Other 0.0 0.0 0.0 0.0 0.0 0.0
† Wald F-test for statistical significance (p<.001) [logistic regression] that all groups are equal.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
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Table 8: Sedatives or Tranquillisers and Anti-depressants Prevalence by Housing Tenure (%)













Total Weighted N (valid responses) 5069 5069 5069 5066 5065 5065
Owned in part or full 14.3 6.6 2.6 9.9 4.4 3.9
Rented from private landlord 10.7 5.0 2.4 8.3 3.6 2.5
Rented from LA/HA 19.6 10.4 5.9 21.5 11.6 10.5
Other 6.9 3.9 0.0 1.8 1.8 0.0
† Wald-F test for statistical significance (p<.001) [logistic regression] that all groups are equal.
 Due to weighting, work status categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 9: Sedatives or Tranquillisers and Anti-depressants Prevalence by Age Education Ceased (%)













Total Weighted N (valid responses) 3892 3892 3892 3891 3890 3890
15 years and under 20.4 9.5 6.9 18.7 10.4 9.1
16–19 years 14.4 7.0 3.6 10.9 5.5 4.9
20 years and over 15.1 6.7 1.9 10.5 4.0 3.3
† Wald-F test for statistical significance (p<.001) [logistic regression] that all groups are equal.
†† Wald-F significance test (p<.001) that the prevalence among those who ceased education at 15 years and under, is larger than among those who ceased 
education at 16 years and over.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
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Table 10: Sedatives or Tranquillisers and Anti-depressants Prevalence by Highest Qualification Level Attained (%)













Total Weighted N (valid responses) 5087 5087 5087 5084 5083 5083
Primary 13.9 7.1 4.5 12.3 7.1 5.9
Lower second level 13.4 6.3 3.4 10.0 4.7 4.0
Upper second level 11.1 6.0 2.4 9.7 4.6 4.2
Third level 15.6 6.6 2.3 10.6 4.5 3.7
† Wald F-test for statistical significance (p<.001) [logistic regression] that all groups are equal.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 11: Sedatives or Tranquillisers and Anti-depressants Prevalence by Marital Status (%)













Total Weighted N (valid responses) 5121 5121 5121 5119 5118 5118
Single 11.4 5.6 1.8 8.2 4.2 3.3
Married 14.2 6.3 2.9 10.6 4.5 4.1
Co-habiting 15.6 7.6 2.0 13.0 5.2 4.7
Separated 24.3 10.6 8.2 19.0 10.1 8.0
Divorced 25.3 16.9 12.3 26.4 15.0 11.5
Widowed 29.4 15.0 11.2 11.3 7.6 5.6
† Wald F-test of statistical significance (p<.001) [logistic regression] that all groups are equal.
 Due to weighting marital status categories do not sum to the weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
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Northern Ireland
Table 14a: Sedatives or Tranquillisers – Prevalence Rates (%)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 2002 2535 993 1262 1009 1272 844 1069 1150 1463
Lifetime Prevalence (Ever used) 20.2 20.7 18.1 17.2 22.3 24.1 11.7 13.6 26.5 25.8
Last Year Prevalence (Recent use) 9.2 11.0 8.2 9.4 10.2 12.7 4.6 6.4 12.6 14.3
Last Month Prevalence (Current use) 7.1 8.0 5.7 7.3 8.4 8.7 2.3 3.6 10.7 11.2
Due to weighting, gender and/or age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 14b: Anti-depressants – Prevalence Rates (%)
All adults  
15–64
Males Females Young adults 
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 2000 2535 992 1263 1009 1272 843 1069 1150 1464
Lifetime Prevalence (Ever used) 21.0 21.9 13.4 15.3 28.4 28.4 13.6 13.6 26.6 28.0
Last Year Prevalence (Recent use) 9.1 12.0a 5.8 8.9a 12.4 15.2 5.8 7.1 11.7 15.7a
Last Month Prevalence (Current use) 7.5 10.2a 4.2 7.6a 10.7 12.8 4.2 5.0 10.0 14.0a
a Denotes a significant change (p<0.05) between 2006/7 and 2010/11.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 15a: Age of First Use of Sedatives or Tranquillisers (All Users) (%)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 404 519 179 215 225 307 99 144 304 377
Median age of first useb 30 32 30 31 30 32 18 20a 35 38
Due to weighting, gender and/or age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 15b: Age of First Use of Anti-depressants (All Users) (%)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 419 554 132 193 287 361 114 145 305 409
Median age of first useb 32 32 34 35 31 32 21 20 37 37
a Significant change (p<0.05) between 2006/7 and 2010/11.
b Median is used as a measure of central tendency to avoid extreme values skewing results.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Table 16a: Frequency of Use of Sedatives or Tranquillisers per Month (Current Users) (%)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 142 203 57 92 85 111 19 38 123 164
20 days or more 65.6 69.1 50.2 69.6 75.8 68.7 51.1 54.9 67.8 72.9
10–19 days 7.2 9.0 11.7 7.7 4.2 10.0 0.0 9.2 8.3 8.4
4–9 days 12.6 10.0 20.4 11.0 7.4 9.1 34.6 15.6 9.2 8.7
1–3 days 14.7 12.0 17.7 11.8 12.7 12.1 14.3 20.4 14.7 10.1
Due to weighting, gender and/or age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 16b: Frequency of Use of Anti-depressants per Month (Current Users) (%)
All adults  
15–64
Males Females Young adults  
15–34
Older adults  
35–64
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 150 259 42 96 108 162 35 53 115 205
20 days or more 86.8 93.6 70.9 92.7 93.0 94.2 74.4 89.1 90.6 94.8
10–19 days 3.4 3.0 6.4 4.8 2.3 2.0 8.0 3.7 2.0 2.9
4–9 days 4.6 2.4 9.6 2.6 2.7 2.2 12.9 5.8 2.1 1.5
1–3 days 5.1 1.0 13.1 0.0 2.0 1.5 4.7 1.4 5.2 0.9
a significant change (p<0.05) between 2006/7 and 2010/11.
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
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Table 17: Method of Taking Sedatives or Tranquillisers and Anti-depressants (Current Users) (%)



















Total Weighted N (valid responses) 203 92 111 38 161 259 96 161 53 205
Oral (Tablets or Syrup) 99.1 97.9 100.0 100.0 98.8 99.3 100.0 98.9 100.0 99.1
Injection with a Needle 0.5 1.0 0.0 0.0 0.6 0.7 0.0 1.1 0.0 0.9
Other 0.5 1.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0
Due to weighting categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 18: How Sedatives or Tranquillisers and Anti-depressants were Obtained (Current Users) (%)



















Total Weighted N (valid responses) 203 92 111 38 164 259 96 162 53 205
I got them on prescription 95.0 93.1 96.6 82.5 98.0 98.7 100.0 97.9 94.9 99.7
I got them from someone I know 2.6 4.4 1.2 13.9 0.0 0.3 0.0 0.5 1.4 0.0
I bought them without a prescription  
in a chemist
1.6 1.0 2.2 0.0 2.0 1.0 0.0 1.6 3.7 0.3
I bought them over the Internet 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Other 0.7 1.5 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0
Due to weighting, categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 19: Sedatives or Tranquillisers and Anti-depressant Prevalence by Gender (%)
Sedatives or Tranquillisers Anti-depressants
Male Female Total Male Female Total
Total Weighted N (valid responses) 1262 1272 2535 1263 1272 2535
Lifetime Prevalence (Ever used)ab 17.2 24.1 20.7 15.3 28.4 21.9
Last Year Prevalence (Recent use)ab 9.4 12.7 11.0 8.9 15.2 12.0
Last Month Prevalence (Current use)b 7.3 8.7 8.0 7.6 12.8 10.2
Due to weighting, gender and/or age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 20: Sedatives or Tranquillisers and Anti-depressant Prevalence by Age Group (%)














Total Weighted N (valid responses) 1069 1469 2535 1069 1464 2535
Lifetime Prevalence (Ever used)ab 13.6 25.8 20.7 13.6 28.0 21.9
Last Year Prevalence (Recent use)ab 6.4 14.3 11.0 7.1 15.7 12.0
Last Month Prevalence (Current use)ab 3.6 11.2 8.0 5.0 14.0 10.2
a p<0.05 (sedatives or tranquillisers).
b p<0.05 (anti-depressants).
 Due to weighting, gender and/or age categories do not always sum to total weighted N.
 All figures are based on weighted data.
 All figures are rounded to the nearest decimal place.
 All figures are based on valid responses.
Drug use in Ireland and Northern Ireland: 2010/11 Drug Prevalence Survey:  
Sedatives or Tranquillisers and Anti-depressants Results
25National Advisory Committee on Drugs (2012)
Table 21: Sedatives or Tranquillisers and Anti-depressants Prevalence by National Statistics Socio-economic 
Classification (%)













Total Weighted N (valid responses) 2527 2529 2527 2530 2528 2529
Managerial and professional occupations 19.9 8.8 5.0 20.1 9.5 8.0
Intermediate occupations 24.2 11.2 8.0 23.1 12.2 10.5
Small employers and own account workers 18.4 10.4 8.4 16.8 10.0 9.2
Lower supervisory and technical occupations 20.3 12.7 9.9 23.1 13.3 9.8
Semi-routine and routine occupations 24.0 14.5 11.5 27.3 15.7 13.9
Never worked and long-term unemployed 26.5 15.4 11.1 32.7 22.2 16.7
Not classified 3.9 1.4 0.5 2.9 0.5 0.0
Total 20.7 11.0 8.0 21.9 12.0 10.2
Due to weighting NSSEC categories do not sum to the weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 22: Sedatives or Tranquillisers and Anti-depressants Prevalence by Work Status (%)













Total Weighted N (valid responses) 2534 2533 2533 2535 2532 2533
In paid work 15.5 5.8 3.1 16.2 6.7 5.4
Not in paid work 35.0 23.6 19.3 37.8 25.1 22.0
Other 3.9 1.5 0.5 2.9 0.5 0.0
Total 20.7 11.0 8.0 21.9 12.0 10.2
Due to weighting, work status categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 23: Sedatives or Tranquillisers and Anti-depressants Prevalence by Housing Tenure (%)













Total Weighted N (valid responses) 2525 2528 2526 2528 2527 2524
Own it outright 18.2 9.5 6.9 16.7 8.7 7.5
Buying it with the help of a mortgage or loan 16.3 7.4 4.8 17.4 8.4 6.9
Pay part rent and part mortgage (co-ownership) – – – 18.2 10.0 10.0
Rented from Northern Ireland Housing Executive (NIHE) 34.2 21.0 18.8 41.2 27.9 24.8
Rented from a housing association 38.3 28.4 18.5 34.6 22.0 16.0
Rented privately 22.7 12.1 7.8 24.5 12.3 9.8
Live rent free 10.5 5.3 5.3 10.5 10.5 10.5
Total 20.7 11.0 8.0 21.9 12.0 10.2
Due to weighting housing tenure categories do not sum to the weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
‘-’ Denotes number less than 5.
Table 24: Sedatives or Tranquillisers and Anti-depressants Prevalence by Highest Qualification Level Attained (%)













Total Weighted N (valid responses) 2528 2527 2525 2526 2525 2526
Degree level or higher 16.8 7.5 3.4 16.1 7.5 6.0
Higher Education 21.0 8.8 7.1 19.0 9.5 8.5
GCE/A Level 15.9 7.2 4.3 17.6 8.7 7.0
GCSE A-C level 21.1 11.4 8.7 24.7 13.6 11.2
GCSE D-G level 22.4 14.2 9.3 21.1 11.8 9.9
No qualifications 26.8 16.9 14.6 29.3 18.5 16.3
Total 20.7 11.0 8.0 21.9 12.0 10.2
Due to weighting, categories do not sum to the weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 25: Sedatives or Tranquillisers and Anti-depressants Prevalence by Marital Status (%)













Total Weighted N (valid responses) 2532 2529 2529 2534 2531 2529
Single 17.1 8.8 6.0 17.2 9.8 7.9
Married 19.2 9.1 7.0 18.4 9.2 8.1
Co-habiting 21.1 9.3 4.3 20.5 10.6 6.8
Separated 33.6 22.1 17.0 54.0 35.4 31.3
Divorced 42.9 28.0 22.0 60.3 32.2 27.5
Widowed 36.1 29.5 23.0 31.1 23.0 19.7
A civil partner in a legally recognised civil partnership – – – 0.0 0.0 0.0
Total 20.7 11.0 8.0 21.9 12.0 10.2
Due to weighting marital status categories do not sum to the weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
‘-’ Denotes number less than 5.
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